Foregoing ICD implantation in patients presenting with ventricular tachycardia: is catheter ablation alone sufficient?

نویسندگان

  • Erik Wissner
  • Karl-Heinz Kuck
چکیده

Ventricular tachycardia (VT) in the setting of structural heart disease (SHD) and a reduced ejection fraction (EF) of ≤35% is commonly treated by insertion of an implantable cardioverter-defibrillator (ICD). While the strategy of secondary prevention reduces mortality, the presence of an ICD has no impact on recurrent episodes of VT. Hence, antiarrhythmic drug therapy is frequently established in order to prevent future arrhythmic events. Use of potent drugs such as amiodarone is hampered by a multitude of side effects, often leading to drug discontinuation by the patient. Since VT in patients with SHD is commonly due to macro-re-entry within the ventricles, catheter ablation has become an attractive means to terminate VT acutely (Table 1). The first prospective randomized trial, SMART VT, demonstrated that patients with coronary artery disease (CAD) presenting with aborted sudden cardiac death, syncope, or unstable VT/ventricular fibrillation (VF) benefit from catheter ablation, resulting in a significant reduction of appropriate ICD shocks. There was also a trend towards a lower number of deaths in the catheter ablation group. A second prospective randomized multicentre trial, VTACH, examined the role of catheter ablation inpatientswithunderlyingCADpresentingwith afirstepisodeof stable VT. Again, a significant reduction in appropriate ICD therapy was seen. Hence, catheter ablation is a viable option in patients with CAD presenting with VT and is supported by the highest degree of evidence as outlined above. However, currently patients are likely to undergo ICD implantation irrespective of the outcome of catheter ablation based on a class I recommendation as set forth in current guidelines. In addition, a significant number of patients may present with arrhythmia recurrence following successful catheter ablation (SMART VT, 12% of patients during 22.5+5.5 months of follow-up; VTACH, 50% of patients with appropriate ICD intervention during 22.5+9.0 months of follow-up). Of interest, in VTACH, those patients with CAD and only mild to moderately reduced EF (.30%) benefited most from catheter ablation. In this context, the study of Maury et al. analysed the outcome of patients with SHD and a reduced EF .30% undergoing catheter ablation for stable, well-tolerated VT without subsequent implantation of an ICD as recommended by current guidelines. Data were collected retrospectively from eight European centres. A total of 166 patients (84% male) met the selection criteria and were included in the analysis. The majority of patients suffered from CAD (55%), while nearly one-third of patients had underlying non-ischaemic cardiomyopathy (19%) or arrhythmogenic right ventricular dysplasia (12%). A group of 378 patients with similar diagnoses undergoing catheter ablation of VT followed by ICD placement served as a nonmatched control group. Upon a mean follow-up period of 32+27 months, all-cause mortality was 12%,whileonly4/166 (2.4%)patients died suddenly. In the control group, all-cause mortality was identical at 12%. The authors concluded that patients with SHD and mild to moderately suppressed EF .30% have a low risk of dying from an arrhythmic cause and, based on their retrospective data, a prospective randomized multicentre trial would be warranted comparing a strategy of catheter ablation with and without subsequent implantation of an ICD. While the time would be right to perform such a trial, there are several issues that need to be discussed when interpreting the data presented by Maury and colleagues. First, this was a retrospective study analysing data from a mixed patient cohort presenting with a variety of underlying cardiac pathologies with significant differences in the natural course of disease progression. Secondly, there was no standardized protocol that was followed during catheter ablation. Thirdly, none of the patients received an ICD. This is contrary to current international guidelines that list placement of an ICD as a

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy.

In 1980, Mirowski et al1 implanted the first implantable cardioverter-defibrillator (ICD) in a young female with recurrent ventricular fibrillation and provided an innovative approach to aborted sudden cardiac death (SCD). Although the ICD was considered a treatment of last resort during that incipient stage, subsequent years have witnessed prolific expansion of indications for ICD implantation...

متن کامل

Catheter ablation of ventricular tachycardia in ischaemic and non-ischaemic cardiomyopathy: where are we today? A clinical review.

According to the current guidelines, patients with ischaemic cardiomyopathy (ICM) or non-ischaemic cardiomyopathy (NICM) at risk for sudden cardiac death should undergo implantation of an implantable cardioverter-defibrillator (ICD). Although ICDs effectively terminate ventricular arrhythmias, the arrhythmogenic substrate remains unchanged or may progress over time, resulting in recurrent ICD s...

متن کامل

Catheter ablation for ventricular tachyarrhythmia in patients with channelopathies

Drug treatment and/or implantable cardioverter defibrillator (ICD) implantation are the most widely accepted first-line therapies for channelopathic patients who have recurrent syncope, sustained ventricular tachycardia (VT), or documented ventricular fibrillation (VF), or are survivors of cardiac arrest. In recent years, there have been significant advances in mapping techniques and ablation t...

متن کامل

ICD Therapy In RVOT-VT And Early Stage ARVD/C Patients.

Implantable cardioverter-defibrillators (ICDs) improve the survival of patients with ischemic or non-ischemic cardiomyopathy and a reduced ejection fraction. However, the efficacy of ICD therapy in patients with right ventricular outflow tract ventricular tachycardia (RVOT-VT) and early stage arrhythmogenic right ventricular dysplasia / cardiomyopathy (ARVD/C) has not been well clarified. Altho...

متن کامل

Risks and Benefits of Catheter Ablation of Ventricular Tachycardia in Patients with an Implantable Cardioverter-Defibrillator

Patients with an implantable cardioverterdefibrillator (ICD) may receive frequent shocks or antitachycardia pacing for monomorphic ventricular tachycardia despite suppressive drug therapy. Antitachycardia pacing is often well-tolerated but not always effective. High voltage cardioversion is usually painful and may cause severe, disabling anxiety for some patients. Therefore, catheter ablation i...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • European heart journal

دوره 35 22  شماره 

صفحات  -

تاریخ انتشار 2014